rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    HCWB
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      HCW Biologics Reports Third Quarter 2026 Business and Clinical Development Highlights and Financial Results

      MIRAMAR, Fla., Nov. 16, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a clinical-stage biopharmaceutical company focused on developing transformative fusion immunotherapeutics to treat autoimmune diseases, cancer and senescence-associated dysplasia, today reported financial results and recent business highlights for the three and nine months ended September 30, 2026. The Company featured two of its preclinical, non-Fc TRBC molecules at the 41st An

      Nov 16Yahoo FinanceHCWB
      HCW Biologics presents cancer therapy data at SITC meeting
      Nov 6Investing.comHCWB
      HCW Biologics’ Presentation for HCW11-040 Recognized for Scientific Rigor, Novelty, Clarity and Potential Impact on Cancer Immunotherapy by the Society for Immunotherapy of Cancer

      Designated as one of the Top 150 abstracts submitted for the 41st Annual Meeting of the Society for Immunotherapy of Cancer HCW11-040 is a first-in-class, second-generation, tetravalent pembrolizumab (Keytruda®) based immune checkpoint inhibitor, built with Company’s proprietary non-Fc TRBC platform HCW11-040 was constructed with interleukin domains (IL-15 and IL-7) paired with a TGF-β trap, that in combination can potentially rejuvenate exhausted T cells for more effective cancer cell killing H

      Nov 6Yahoo FinanceHCWB
      HCW Biologics Presents Newly Identified Distinctive Features of Its Lead T Cell Engager Candidate Built with Company’s Proprietary T-Cell Engager Platform, Further Supporting Its Use in Treating Solid Tumors at the Society for Immunotherapy of Cancer’s 41
      Nov 6Yahoo FinanceHCWB
      HCW Biologics secures up to $10M debt financing for phase 1 study
      Nov 5Investing.comHCWB
      HCW Biologics Secures up to $10.0 Million in Cash Through Debt Financing
      Nov 5Yahoo FinanceHCWB
      Wall Street Analysts Are Bullish on Top Healthcare Picks

      Detailed price information for Hcw Biologics Inc (HCWB-Q) from The Globe and Mail including charting and trades.

      Oct 11The Globe and MailATOSHCWB
      HCW Biologics receives FDA guidance for cancer drug trial
      Oct 9Investing.comHCWB
      HCW Biologics Maintains Momentum Toward Completion of IND Application for Clinical Study to Evaluate Lead T-Cell Engager in Solid Tumors
      Oct 9Yahoo FinanceHCWB
      HCW Biologics prices $1.5M private placement offering
      Sep 24Investing.comHCWB
      HCW Biologics Signs Akron Biotech Distribution Deal for CAR-T Manufacturing Reagent

      HCW Biologics Inc. (NASDAQ:HCWB) has entered into an exclusive distribution agreement with Akron Biotech covering HCW11-006, its multi-cytokine fusion molecule designed for use as a reagent in CAR-T cell manufacturing.

      Sep 8Yahoo FinanceHCWB
      HCW Biologics signs distribution deal with Akron Biotech
      Sep 8Investing.comHCWB
      HCW Biologics Entered an Exclusive Distribution Agreement with Akron Biotech to Commercialize HCW11-006 as Reagent Used to Support Production of Highly Functional Human CAR-T Cells

      Agreement includes pre-payment commitments for product sales and distribution of the second-generation multi-cytokine-based HCW11-006 for use as a reagent Akron is a leading supplier of critical ancillary materials and accessory molecules for clinical and commercial scale-up of cell, gene and regenerative therapy products HCW Biologics supplies research and cGMP-grade HCW11-006 and Akron markets and distributes the reagent to its established network of research institutions and commercial compan

      Sep 8Yahoo FinanceHCWB
      HCW Biologics Strengthens U.S. Patent Estate for Its Lead Clinical-Stage Immunotherapeutic HCW9302 as Alopecia Areata Treatment
      Sep 2Yahoo FinanceHCWB
      HCW Biologics’ TGF-β Trap and IL-15 Fusion is a Novel Moiety to Enhance Immunotherapeutic Activity against Diseased Cells

      Human studies show that the TGF-β trap and IL-15 fusion used alone promotes expansion of progenitor CD8+ T cells and NK cells Company has incorporated the TGF-β/IL-15 moiety into the constructs of its second-generation fusion immunotherapeutics constructed with novel TRBC drug development platform MIRAMAR, Fla., Aug. 25, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the “Company” or “HCW Biologics”) (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on developing novel

      Aug 25Yahoo FinanceHCWB
      HCW Biologics advances cancer therapies with TGF-β/IL-15 fusion
      Aug 25Investing.comHCWB

      This is the newest page. Registered accounts read further back.